Gamma-glutamyl transferase: A novel cardiovascular risk biomarker

Preventive Cardiology

Volumn 13, Issue 1, 2010, Pages 36-41

  Mason, Jennifer E ^a   Starke, Rodman D ^b   Van Kirk, John E ^c  

^a Berkeley HeartLab Inc   (United States)

^b AMERICAN HEART ASSOCIATION   (United States)

^c Mills Peninsula Health Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ALCOHOL CONSUMPTION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER FUNCTION TESTS; METABOLIC SYNDROME X; OXIDATIVE STRESS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 72549098792     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2009.00054.x     Document Type: Review

References (30)

1. Ryu S, Chang Y, Kim DI. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem 2007, 53:71-77.
2. Paolicchi A, Emdin M, Passino C. Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis 2006, 186:80-85.
3. Sacchetti L, Castaldo G, Fortunato G. Improved procedure for measuring gamma-glutamyltransferase isoenzymes in serum. Clin Chem 1988, 34:419-422.
4. Ortega E, Koska J, Salbe AD. Serum gamma-glutamyl transpeptidase is a determinant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006, 91:1419-1422.
5. Yki-Jarvinen H. Ectopic fat accumulation: an important cause of insulin resistance in humans. J R Soc Med 2002, 95(suppl 42):39-45.
6. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998, 21:732-737.
7. Nannipieri M, Gonzales C, Baldi S. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005, 28:1757-1762.
8. Nilssen O, Forde OH, Brenn T. The Tromso study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990, 132:318-326.
9. Conigrave KM, Saunders JB, Reznik RB. Prediction of alcohol-related harm by laboratory test results. Clin Chem 1993, 39:2266-2270.
10. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
11. Paolicchi A, Emdin M, Ghliozeni E. Images in cardiovascular medicine. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation 2004, 109:1440.
12. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
13. Ridker PM, Brown NJ, Vaughan DE. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004, 109:IV6-IV19.
14. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995, 142:699-708.
15. Lee DH, Jacobs DR, Gross M. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003, 49:1358-1366.
16. Meisinger C, Lowel H, Heier M. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005, 258:527-535.
17. Rantala AO, Lilja M, Kauma H. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 2000, 248:230-238.
18. Ruttmann E, Brant LJ, Concin H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
19. Giral P, Ratziu V, Chapman JC. Letter regarding article by Ruttmann E, et al. " gamma-Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults" . Circulation 2006, 113:e299-e300.
20. Onat A, Hergenc G, Karabulut A. Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle-aged and elderly adults. Prev Med 2006, 43:136-139.
21. Kazemi-Shirazi L, Endler G, Winkler S. Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem 2007, 53:940-946.
22. Lee DS, Evans JC, Robins SJ. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:127-133.
23. Hanley AJ, Williams K, Festa A. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147.
24. Yamada J, Tomiyama H, Yambe M. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis 2006, 189:198-205.
25. Lee DH, Jacobs DR. Association between serum gamma-glutamyltransferase and C-reactive protein. Atherosclerosis 2005, 178:327-330.
26. Grundy SM. Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 2007, 27:4-7.
27. Emdin M, Passino C, Michelassi C. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol 2009, 136:80-85.
28. Naghavi M, Libby P, Falk E. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664-1672.
29. Naghavi M, Libby P, Falk E. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003, 108:1772-1778.
30. Paolicchi A, Franzini M, Emdin M. The potential roles of gamma-glutamyltransferase activity in the progression of atherosclerosis and cardiovascular diseases. Vascular Disease Prevention 2006, 3:205-209.